Please use this identifier to cite or link to this item: http://dr.iiserpune.ac.in:8080/xmlui/handle/123456789/5964
Title: Therapeutic antibodies, targeting the SARS-CoV-2 spike N-terminal domain, protect lethally infected K18-hACE2 mice
Authors: Noy-Porat, Tal
KIKKERI, RAGHAVENDRA et al.
Dept. of Chemistry
Keywords: Neutralizing Antibodies
Sialic-Acid
Glycoprotein
Ace2
2021-JUN-WEEK4
TOC-JUN-2021
2021
Issue Date: May-2021
Publisher: Elsevier B.V.
Citation: iScience, 24(5), 102479.
Abstract: Neutralizing antibodies represent a valuable therapeutic approach to countermeasure the current COVID-19 pandemic. Emergence of SARS-CoV- 2 variants emphasizes the notion that antibody treatments need to rely on highly neutralizing monoclonal antibodies (mAbs), targeting several distinct epitopes for circumventing therapy escape mutants. Previously, we reported efficient human therapeutic mAbs recognizing epitopes on the spike receptor-binding domain (RBD) of SARS-CoV-2. Here we report the isolation, characterization, and recombinant production of 12 neutralizing human mAbs, targeting three distinct epitopes on the spike N-terminal domain of the virus. Neutralization mechanism of these antibodies involves receptors other than the canonical hACE2 on target cells, relying both on amino acid and N-glycan epitope recognition, suggesting alternative viral cellular portals. Two selectedmAbs demonstrated full protection of K18-hACE2 transgenic mice when administered at low doses and late postexposure, demonstrating the high potential of the mAbs for therapy of SARS-CoV-2 infection.
URI: http://dr.iiserpune.ac.in:8080/xmlui/handle/123456789/5964
https://doi.org/10.1016/j.isci.2021.102479
ISSN: 2589-0042
Appears in Collections:JOURNAL ARTICLES

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.